A single-center, prospective, single-arm, phase II trial to evaluate the adjuvant efficacy of camrelizumab with docetaxel plus S-1 for stage III (PD-L1+/dMMR/EBV+) gastric cancer after D2 resection.

医学 多西紫杉醇 内科学 肿瘤科 临床终点 临床研究阶段 佐剂 癌症 外科 化疗 临床试验
作者
Bo Ni,Xiang Xia,Yujing Guan,Linxi Yang,Linhua Ji,Enhao Zhao,Hui Cao,Gang Zhao,Chunchao Zhu,Zizhen Zhang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): e16089-e16089 被引量:1
标识
DOI:10.1200/jco.2023.41.16_suppl.e16089
摘要

e16089 Background: Immunotherapy has demonstrated promising efficacy and favorable safety profile for unresectable or metastatic gastric cancer (GC) by several high-quality studies. However, few have examined the immunotherapy efficacy for locally advanced GC (LAGC) in the perioperative setting, especially as adjuvant therapy after D2 resection. Here, a phase II trial reports the adjuvant efficacy of camrelizumab with docetaxel plus S-1 in patients (pts) with PD-L1 positive, deficient mismatch repair (dMMR) or Epstein-Barr virus (EBV) positive LAGC (NCT04152889). Methods: This is a single-center, prospective, open-label and single-arm phase II study. Chemotherapy-naive adult pts receiving D2 resection and histologically confirmed as PD-L1 positive (CPS > 5), dMMR or EBV positive LAGC (stage III) were enrolled. Pts received camrelizumab (200mg, D1), docetaxel (40mg/m 2 , D1, free at first course) and S-1 (80-120mg, D1-14) every 3 weeks for seven courses, sequenced by camrelizumab (200mg, D1) and S-1 (80-120mg, D1-14) every 3 weeks for up to one year, until disease relapse or intolerable toxicity. Primary endpoint was 1-year relapse-free survival (RFS). Herein, the safety and efficacy data after 1-year postoperative therapy courses were reported. Results: From Jan. 2020 to Jan. 2022, 19 pts (median age 59 years, range 34-75, 13 men and 6 women) were enrolled, of whom 15 were CPS > 5, 3 were dMMR, and 1 was EBV positive. pTNM stage IIIA, B and C were 10 (52.6%), 3 (15.8%) and 6 (31.6%), respectively. The cut-off date for the final follow-up data was Feb. 1, 2023 with a median follow-up period for surviving patients of 25.1 months. All 19 pts had experienced treatment related adverse events (TRAEs), of whom, grade 3-4 TRAEs occurred in 9 (47.4%), 2 pts (10.5%) discontinued therapy, and 11 pts (57.9%) delayed the therapy. Furthermore, the OS rate of 19 pts at 1/2 years was 100% and 88.9%, while the RFS rate at 1/2 years was 100% and 92.3%, respectively. The dead and recurrent cases all belonged to PD-L1 positive subgroup. Conclusions: Adjuvant therapy of camrelizumab with docetaxel plus S-1 shows acceptable safety and promising efficacy for PD-L1 positive, dMMR, or EBV positive stage III GC pts after D2 resection. Clinical trial information: NCT04152889 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
兵王完成签到,获得积分0
刚刚
深情安青的应助被wwwwwnnnnn采纳,获得10
刚刚
香港下雪发布了新的文献求助10
刚刚
西米路完成签到,获得积分10
刚刚
野菜关注了科研通微信公众号
1秒前
1秒前
Qawsed完成签到,获得积分10
2秒前
2秒前
CipherSage的应助被zzl采纳,获得10
2秒前
英俊的铭的应助被dongyu采纳,获得10
3秒前
李健的应助被dongyu采纳,获得10
3秒前
天天快乐的应助被dongyu采纳,获得10
3秒前
大模型的应助被dongyu采纳,获得10
3秒前
今后的应助被dongyu采纳,获得10
3秒前
科研通AI2S的应助被dongyu采纳,获得10
3秒前
无花果的应助被dongyu采纳,获得10
3秒前
顾矜的应助被dongyu采纳,获得10
3秒前
小二郎的应助被凤凰院凶真采纳,获得10
4秒前
小王发布了新的文献求助10
4秒前
十年完成签到 ,获得积分10
4秒前
4秒前
DXDPG发布了新的文献求助10
4秒前
觉皇发布了新的文献求助10
5秒前
5秒前
mk发布了新的文献求助10
5秒前
学术雷锋发布了新的文献求助10
5秒前
molihuakai的应助被科研通管家采纳,获得10
6秒前
6秒前
sunny的应助被科研通管家采纳,获得10
6秒前
所所的应助被科研通管家采纳,获得10
6秒前
6秒前
充电宝的应助被科研通管家采纳,获得80
7秒前
SYJ完成签到,获得积分10
7秒前
7秒前
stardust314的应助被科研通管家采纳,获得10
7秒前
7秒前
sunny的应助被科研通管家采纳,获得10
7秒前
7秒前
sunny的应助被科研通管家采纳,获得10
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170787
求助须知:如何正确求助?哪些是违规求助? 9563660
关于积分的说明 21771326
捐赠科研通 7762279
什么是DOI,文献DOI怎么找? 3430761
关于科研通互助平台的介绍 2554585
邀请新用户注册赠送积分活动 2475525